HSE approval of breast cancer drug is considered a ‘significant milestone’ – TheLiberal.ie – Our News, Your Views

HSE approval of breast cancer drug is considered a ‘significant milestone’




A “significant milestone” has been reached with the HSE’s approval of a novel treatment option that might lower the risk of recurrence of breast cancer by 30% in patients at high risk of the disease, reports RTE.

The pharmaceutical business Eli Lilly produces the medication, abemaciclib, which is prescribed to patients with high-risk oestrogen-driven breast cancer.

Oncologists state that oestrogen-driven breast cancer accounts for around 70% of all cases and that a significant risk of recurrence exists in about 25% of these instances, reports RTE.

The medication will be supplied as a pill to qualified individuals for a period of two years.

It will be accessible as of June 1st, reports RTE.

Tell us your thoughts in the Facebook post and share this with your friends.

Share this story with a friend

Share this story

Tell us what you think on our Facebook page